The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis
Objective Calreticulin (CALR) mutations have been identified as driver mutations in a quarter of patients with essential thrombocythaemia (ET) and primary myelofibrosis (PMF), which are subgroups of myeloproliferative neoplasms (MPNs). A 52-bp deletion (type I mutation) and a 5-bp insertion (type II...
| Published in: | Hematology |
|---|---|
| Main Authors: | Yuxia Pan, Xingzhe Wang, Shupeng Wen, Xiaojun Liu, Lin Yang, Jianmin Luo |
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2107888 |
Similar Items
Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01)
by: Mahija Cheekati, et al.
Published: (2024-04-01)
Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)
by: L. A. Kesaeva, et al.
Published: (2019-07-01)
CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)
by: E. G. lisina, et al.
Published: (2017-10-01)
The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)
by: Mostafa Najim, et al.
Published: (2024-12-01)
A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide
by: Ekrem Yetiskul, et al.
Published: (2024-02-01)
by: Ekrem Yetiskul, et al.
Published: (2024-02-01)
Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis
by: Michael R. Grunwald, et al.
Published: (2024-08-01)
by: Michael R. Grunwald, et al.
Published: (2024-08-01)
Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real‐World Management of Myeloproliferative Neoplasms
by: Ali Mahdi, et al.
Published: (2025-04-01)
by: Ali Mahdi, et al.
Published: (2025-04-01)
Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review
by: Long Zhao, et al.
Published: (2024-12-01)
by: Long Zhao, et al.
Published: (2024-12-01)
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives
by: Massimo Breccia, et al.
Published: (2024-07-01)
by: Massimo Breccia, et al.
Published: (2024-07-01)
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
by: Jumoke Okikiolu, et al.
Published: (2023-01-01)
by: Jumoke Okikiolu, et al.
Published: (2023-01-01)
Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report
by: Petruta Gurban, et al.
Published: (2023-09-01)
by: Petruta Gurban, et al.
Published: (2023-09-01)
Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
by: Abhinav Mathur, et al.
Published: (2022-11-01)
by: Abhinav Mathur, et al.
Published: (2022-11-01)
Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis
by: T. N. Subbotina, et al.
Published: (2023-03-01)
by: T. N. Subbotina, et al.
Published: (2023-03-01)
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
by: Magda Zanelli, et al.
Published: (2024-03-01)
by: Magda Zanelli, et al.
Published: (2024-03-01)
Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
by: Arturo Bonometti, et al.
Published: (2023-04-01)
by: Arturo Bonometti, et al.
Published: (2023-04-01)
Effects of <i>CALR</i>-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
by: Hyun-Young Kim, et al.
Published: (2022-10-01)
by: Hyun-Young Kim, et al.
Published: (2022-10-01)
The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry
by: Chris Varghese, et al.
Published: (2021-04-01)
by: Chris Varghese, et al.
Published: (2021-04-01)
The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
by: Lai Yee Orbell, et al.
Published: (2023-11-01)
by: Lai Yee Orbell, et al.
Published: (2023-11-01)
Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
by: Velizar Shivarov, et al.
Published: (2024-09-01)
by: Velizar Shivarov, et al.
Published: (2024-09-01)
Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity
by: Fabiola Guerra, et al.
Published: (2022-11-01)
by: Fabiola Guerra, et al.
Published: (2022-11-01)
The relationship between TMCO1 and CALR in the pathological characteristics of prostate cancer and its effect on the metastasis of prostate cancer cells
by: Dong Jingting, et al.
Published: (2024-10-01)
by: Dong Jingting, et al.
Published: (2024-10-01)
Differential regulation of mTORC2 signalling by type I and type II calreticulin (CALR) driver mutations of myeloproliferative neoplasm
by: Saadia Naseer, et al.
Published: (2025-05-01)
by: Saadia Naseer, et al.
Published: (2025-05-01)
Genomics of clonal evolution in a rare essential thrombocythemia with coexisting Type 2 CALR and MPL S204P mutations
by: Jing Wang, et al.
Published: (2023-12-01)
by: Jing Wang, et al.
Published: (2023-12-01)
CalR is an activator of biofilm formation in Vibrio parahaemolyticus
by: Jingyang Chang, et al.
Published: (2025-10-01)
by: Jingyang Chang, et al.
Published: (2025-10-01)
Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
by: T. N. Subbotina, et al.
Published: (2021-06-01)
by: T. N. Subbotina, et al.
Published: (2021-06-01)
A rare CALR exon 9 mutation p.E379Vfs*53 in AYA generation exhibits gain-of-function nature and can induce essential thrombocythemia; a case report
by: Keiki Nagaharu, et al.
Published: (2025-12-01)
by: Keiki Nagaharu, et al.
Published: (2025-12-01)
Clinical meaning of JAK2 V617F mutation in chronic myeloproliferative disorders – the first experience
by: Joško Vučković, et al.
Published: (2006-10-01)
by: Joško Vučković, et al.
Published: (2006-10-01)
Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)
Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)
Mechanism of miR-148b inhibiting cell proliferation and migration of Schwann cells by regulating CALR
by: Zhenyu Zhou, et al.
Published: (2019-12-01)
by: Zhenyu Zhou, et al.
Published: (2019-12-01)
Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
by: Barnali Srivastava, et al.
Published: (2023-09-01)
by: Barnali Srivastava, et al.
Published: (2023-09-01)
Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
by: Lewis Carpenter, et al.
Published: (2022-08-01)
by: Lewis Carpenter, et al.
Published: (2022-08-01)
Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01)
by: Lingzhi Zhong, et al.
Published: (2025-07-01)
Myelofibrosis: An unusual presentation of disseminated tuberculosis
by: Neha Sharma, et al.
Published: (2020-01-01)
by: Neha Sharma, et al.
Published: (2020-01-01)
Targeted Therapy of Myelofibrosis
by: OYu Vinogradova, et al.
Published: (2017-10-01)
by: OYu Vinogradova, et al.
Published: (2017-10-01)
CORRELATION BETWEEN JAK2V617F MUTATIONAL BURDEN AND THE DEGREE OF ANGIOGENESIS IN THE BONE MARROW OF BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
by: Liana Gercheva, et al.
Published: (2014-09-01)
by: Liana Gercheva, et al.
Published: (2014-09-01)
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
by: Julian Grabek, et al.
Published: (2020-08-01)
by: Julian Grabek, et al.
Published: (2020-08-01)
Possibilities of targeted therapy for myelofibrosis: Moscow experience
by: O. Yu. Vinogradova, et al.
Published: (2022-11-01)
by: O. Yu. Vinogradova, et al.
Published: (2022-11-01)
An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
by: Nicola Orofino, et al.
Published: (2017-01-01)
by: Nicola Orofino, et al.
Published: (2017-01-01)
Molecular study of CALR gene mutations in children with leukemia hospitalized
in Kerman hospitals
by: Farzaneh Parnak, et al.
Published: (2020-03-01)
by: Farzaneh Parnak, et al.
Published: (2020-03-01)
Similar Items
-
Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01) -
Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01) -
CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01) -
The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01) -
A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide
by: Ekrem Yetiskul, et al.
Published: (2024-02-01)
